James Matera, MD, on Treating Hep C in ESRD, Renal Transplant Candidates

 

Dr James Matera from CentraState Medical Center in Freehold, NJ, details advances in the treatment of hepatitis C virus in patients with end-stage renal disease, and explains why it may be beneficial to defer hepatitis C treatment until after renal transplant candidates have undergone their procedure.

James J. Matera DO, FACOI, is the Medical Director of Population Health at CentraState Medical Center in Freehold, New Jersey.

ADDITIONAL READING:

1. Durand CM, Bowring MG, Brown DM, et al. Direct-acting antiviral prophylaxis in kidney transplantation from hepatitis C virus-infected donors to non-infected recipients: an open-label nonrandomized trial. Ann Intern Med. 2018;168(8):533-540. doi:10.7326/M17-2871.

2. Reese PP, Abt PL, Blumberg EA, et al. Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: a single-group trial. Ann Intern Med. 2018;169(5):273-281. doi:10.7326/M18-0749.

Submit Feedback

Name